Dan Tilley joined EAG as Chief Information Officer in October, 2015.
Prior to joining EAG, Dan was the CIO and EVP at ClubCorp where he worked in roles of increasing responsibility for eight years. ClubCorp is a publicly traded company with 20,000+ full time and seasonal employees and 200 locations. Dan served as President of the company’s 503c, Employee Partner Care Foundation which provided over $2m in grants. He oversaw a project to centralize their billing system resulting in reduced annual operating expenses by $4 million and reduced IT and Accounting costs by $15 million annually by implementing a multi-year outsourcing plan.
Dan was a founding partner of Brightstar Golf Group and filled a variety of roles for the start up.
Before, Dan Tilley was CIO and VP Finance at Spectrum Clubs, in the health and fitness market with 100k members. During his 4 years, he managed numerous cost cutting initiatives for IT, accounting and finance functions.
Dan was the VP and CIO at Cobblestone Golf Group where he had responsibility for IT, District Accounting, Training/Transitions, Internal Audit, Staffing, and Reporting.
Dan received a BS from University of Pittsburgh in Computer Science and Mathematics.
Eurofins EAG Laboratories, a global leader in materials testing services, is expanding its advanced microscopy capabilities with a new 6,800 square-foot laboratory in Phoenix, AZ.
February 12, 2025
During this live Ask the Expert event, we will answer pre-submitted questions from our audience regarding Silicon Carbide for High Powered Electronics. EAG Laboratories has a vast depth of experience analyzing silicon carbide using both bulk and spatially resolved analytic techniques and is the world-leading materials characterization and engineering resource for semiconductor testing.
Wednesday, March 26, 2025
In this webinar, we will show you how Eurofins EAG supports you in the various phases of reliability testing to come to a robust product, including the different types of actual testing.
EAG offers advanced expertise and a risk-based approach for medical device extractable study design and execution, including the latest FDA expectations.
To enable certain features and improve your experience with us, this site stores cookies on your computer. Please click Continue to provide your authorization and permanently remove this message.
To find out more, please see our privacy policy.